Your browser doesn't support javascript.
loading
Dexmedetomidine: A Novel Strategy for Patients with Intractable Pain, Opioid-Induced Hyperalgesia, or Delirium at the End of Life.
Hofherr, Mara Lacy; Abrahm, Janet L; Rickerson, Elizabeth.
Afiliación
  • Hofherr ML; Psychosocial Oncology and Palliative Care, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
  • Abrahm JL; Psychosocial Oncology and Palliative Care, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
  • Rickerson E; Department of Palliative Care, Brigham and Women's Hospital, Boston, Massachusetts, USA.
J Palliat Med ; 23(11): 1515-1517, 2020 11.
Article en En | MEDLINE | ID: mdl-31944877
ABSTRACT
Dexmedetomidine, a selective alpha2 agonist, is traditionally used briefly for perioperative anesthesia and sedation of mechanically ventilated patients. Reports of its use in patients with opioid-induced hyperalgesia1 and intractable pain and delirium2 suggested it for patients who otherwise may have required palliative sedation to relieve suffering. We present the protocol developed by the interdisciplinary team in our intensive palliative care unit that allows for safe titrated administration without required vital sign monitoring outside the intensive care unit (ICU) (Supplementary Appendix SA1). We describe its efficacy in eight patients who were receiving comfort-focused care.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dolor Intratable / Dexmedetomidina / Delirio Límite: Humans Idioma: En Revista: J Palliat Med Asunto de la revista: SERVICOS DE SAUDE Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Dolor Intratable / Dexmedetomidina / Delirio Límite: Humans Idioma: En Revista: J Palliat Med Asunto de la revista: SERVICOS DE SAUDE Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos